Published: 2013-05-17 17:31:59
SUMMARY
Alan Nelson is heading the Predictive Health Analytics Initiative that aims to change the paradigm in healthcare from treating late stage disease to early diagnosis and preventive therapies that are cost-effective. He served as the Executive Director of the Biodesign Institute at ASU and holds professorships in Bioengineering and physics. He is the founder and CEO of three companies, the most recent being VisionGate, the innovator of the LuCED lung cancer early detection test. VisionGate was awarded the start-up of the year award at the recent Governors’ celebration of innovation. Alan has a PhD in Biophysics from Berkeley, holds 66 issued patents, and has published over 100 scholarly papers in biomedical imaging.